Lorqess' Slight Efficacy, Potential Safety Issues Leave Arena On The Hot Seat At Advisory Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA seeks input on the "slim margin" of efficacy and the adequacy of safety data for Arena's obesity drug.